GREY:DGCRF - Post Discussion
Post by
Dibah42 on Jun 03, 2013 4:23pm
HOLX dithering..?
"Because the concept that PCA3 can become a product of reference to help better diagnose prostate cancer patients is becoming more and more evident in the clinical community, we are in the midst of a productive dialogue with Hologic's management regarding ways to optimize the value of PCA3 for both companies."
Translated: HOLX has been doing diddley squat in sales and marketing efforts for Progensa thus far.
The 21% increase in US sales is primarily due to price increases and (probably) not unit sales increase.
Be the first to comment on this post